BiotechTube

daraxonrasib

Phase 3Recruiting
2 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Cancer

Conditions

Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma

Trial Timeline

Dec 15, 2025 → Jul 10, 2030

NCT ID
NCT07252232

About daraxonrasib

daraxonrasib is a phase 3 stage product being developed by REVOLUTION Medicines for Pancreatic Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07252232. Target conditions include Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma.

What happened to similar drugs?

9 of 20 similar drugs in Pancreatic Cancer were approved

Approved (9) Terminated (4) Active (11)
✅DalteparinEisaiApproved
✅CREONAbbVieApproved
✅Pancrelipase + PlaceboAbbVieApproved
✅Pancrelipase CapsulesAbbVieApproved
✅Chromogranin ANovartisApproved
✅Pasireotide + DiazoxideNovartisApproved
✅everolimusNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07252232Phase 3Recruiting

Competing Products

20 competing products in Pancreatic Cancer

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
pemetrexedEli LillyPhase 2
35
mFOLFIRINOX + RamucirumabEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
enzastaurin + gemcitabineEli LillyPhase 2
35
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
29
RamucirumabEli LillyPhase 1/2
32
GEMZAR + ALIMTAEli LillyPhase 3
40
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
35
exatecan mesylateDaiichi SankyoPhase 2
35
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
40
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
35
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
29
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
29
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
35
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
40